Last checked at 8 Jun 2022 13:52
8 June 2022
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Results of Annual General Meeting
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that at the Company's Annual General Meeting held today at 11 am at the Offices of Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, all resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 29 April 2022.
The poll results were as follows.
Resolution
| Title | For (see note 2) | Against (see note 2) | ||
No. of shares | % | No. of shares | % | ||
1 | Receive Annual Report and Accounts | 122,189,273 | 99.99 | 2,000 | 0.01 |
2 | Approve the Remuneration Report | 121,168,966 | 99.02 | 1,198,956 | 0.98 |
3 | Re-appoint Deloitte LLP as auditors | 116,797,783 | 95.92 | 4,969,411 | 4.08 |
4 | Re-elect Peter Allen | 103,388,287 | 89.10 | 12,651,027 | 10.90 |
5 | Re-elect Grahame Cook | 113,183,101 | 92.49 | 9,190,030 | 7.51 |
6 | Elect Douglas Le Fort | 115,464,984 | 99.27 | 844,330 | 0.73 |
7 | Re-elect Chris Meredith | 120,304,522 | 98.31 | 2,068,609 | 1.69 |
8 | Re-elect Eddie Johnson | 122,028,446 | 99.72 | 344,685 | 0.28 |
9 | Declare final dividend | 122,378,935 | 99.99 | 1,121 | 0.01 |
10 | Authorise allotment of shares | 117,948,199 | 96.38 | 4,430,807 | 3.62 |
11 | Disapply pre-emption rights* | 108,025,798 | 88.28 | 14,345,022 | 11.72 |
12 | Authorise purchase of own shares* | 94,316,659 | 99.05 | 907,369 | 0.95 |
* Special Resolution
Notes: 1. Votes "For" and "Against" are expressed as a percentage of votes received. 2. A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution. 3. Total number of shares in issue at close of business on 6 June = 216,626,583 shares. 56% of the voting capital was instructed. |
- Ends -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer | |
| |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Mary-Jane Elliott / Matthew Neal / Matthew Cole | AMS@consilium-comms.com |
Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Daniel Adams / Gary Clarence | |
HSBC Bank PLC (Broker) | Tel: 44 (0) 20 7991 8888 |
Sam McLennan / Joe Weaving / Stephanie Cornish |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made four acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products and AFS Medical, a specialist distributor of minimally invasive surgical devices based in Austria.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.